Search | Page 9 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up.

    ... follow-up on 67 SAA patients (44 treatment-naive and 23 refractory ) treated with high-dose cyclophosphamide. At 10 years, the ... was 58% in 44 treatment-naive SAA patients. Patients with refractory SAA fared less well after high-dose cyclophosphamide therapy; at 10 ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ADULTS WITH MYELODYSPLASTIC SYNDROMES (MDS): RELEVANCE OF PRE-TRANSPLANT DISEASE STATUS.

    ... the time of transplant, 53 patients (56%) had relapsed/ refractory disease. The cumulative incidence of grades II-IV acute ...

    Research Article last updated 06/28/2013 - 1:28pm.

  3. Eltrombopag in aplastic anemia

    ... treatment of patients with severe aplastic anemia (SAA) refractory to IST. There is evidence that this drug works by directly ... combination therapy in the upfront treatment of SAA, in IST-refractory SAA and in moderate disease. Bone ...

    Research Article last updated 03/02/2015 - 12:51pm.

  4. Anemia as the Main Manifestation of Myelodysplastic Syndromes

    ... Several new agents are under evaluation for ESA refractory /relapsed MDS patients, targeting different putative mechanisms ...

    Research Article last updated 12/02/2015 - 8:45am.

  5. Immunosuppressive therapy for transplant-ineligible aplastic anemia patients

    ... in first-line treatment and management of relapsing and refractory patients with an emphasis on adult patients. Some promising new ...

    Research Article last updated 03/02/2015 - 1:04pm.

  6. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes

    ... 24-month survival (especially among patients with refractory anemia or refractory anemia with excess blasts ). The magnitude of the cost of ...

    Research Article last updated 10/01/2012 - 9:41am.

  7. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... of 4.5 months) especially for patients who fail ( refractory /relapsed) HMT. The only potential curative treatment for MDS is ...

    Research Article last updated 05/12/2015 - 9:47am.

  8. TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate

    ... period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors. ... curative transplant Relapsed or primary therapy- refractory AML with bone marrow blast < 20% High-risk ...

    Clinical Trial last updated 04/29/2016 - 4:35pm.

  9. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

    ... by an external ambulatory infusion pump in patients with refractory anemia with excess blasts -1, -2, or, -t ...

    Research Article last updated 05/22/2014 - 10:23am.

  10. SF3B1 mutations in patients with myelodysplastic syndromes: the mutation is stable during disease evolution

    ... of 479 MDS patients and 61.8% of 34 patients with refractory anemia with ring sideroblasts (RARS). SF3B1 mutations ...

    Research Article last updated 04/23/2014 - 11:18am.